Delivery Order SPE2DE21D0005-SPE2D625F7LA3
Award Date 7/17/25
Potential Completion Date 7/22/25
Potential Value $3.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Fixed Price with Economic Price Adjustment
Place of Performance
Canton, MA 02021, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
65
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Organogenesis Inc. was awarded a $8,500 delivery order by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product. The contract is structured as a fixed-price agreement with economic price adjustment provisions and is scheduled for completion by July 28, 2025. The work will be performed at Organogenesis' headquarters in Canton, Massachusetts. No set-aside designation was utilized for this award, indicating...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, has been awarded a delivery order by the Defense Logistics Agency (DLA) Medical Supply Chain for PURAPLY AM XT 4.91X4.91 wound care dressings. The fixed-price delivery order, valued at $11,580.00, was awarded on August 15, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, allowing the company to compete as a standard commercial vendor. The place of...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a $17.82K delivery order on September 9, 2025, for PURAPLY SX 6CM x 9CM wound care dressings. This fixed-price contract with economic price adjustment carries an ultimate completion date of September 12, 2025, and is being funded through the Medical Supply Chain, a defense-oriented federal agency. The award was made on a competitive basis with no set-aside designation, reflecting...
- Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, received a delivery order award valued at $1,239.95 from the Defense Logistics Agency's Medical Supply Chain for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 7, 2025, carries a fixed price structure with economic price adjustment provisions and is scheduled for completion by May 12, 2025. No set-aside designation was used in this award, indicating Organogenesis...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $8,500 delivery order to Organogenesis Inc. on August 4, 2025, for PURAPLY AM XT EF 5-layer fenestrated wound care dressing. The contract is fixed-price with economic price adjustment and carries an ultimate completion date of August 7, 2025. The award was made without a set-aside designation, allowing Organogenesis to compete as a standard commercial vendor. Performance will take place at the company's headquarters in...
- The U.S. Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $1,274.00 to Organogenesis Inc. for the supply of PURAPLY Micronized 500mg, an advanced wound care product. The contract, awarded on July 23, 2025, with an ultimate completion date of July 28, 2025, utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation. Organogenesis, a regenerative medicine company headquartered in Canton, Massachusetts, will perform the...
- The U.S. government awarded a $3,400.00 fixed-price delivery order contract to Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts. The contract is for the supply of PURAPLY AM XT EF, a 5-layer fenestrated wound dressing product, with a performance period ending on July 3, 2025. This award was made by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, and is not a set-aside contract. Organogenesis is a manufacturer of advanced wound care,...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $17.82K delivery order to Organogenesis Inc. on August 11, 2025, for PURAPLY SX 6CM X 9CM wound care products, with an ultimate completion date of August 14, 2025. The contract utilizes fixed-price pricing with economic price adjustment and carries no set-aside designation, allowing Organogenesis to compete as a standard commercial vendor. Performance will occur at the contractor's headquarters in Canton,...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $2,479.90 for APLIGRAF on May 30, 2025, with an ultimate completion date of June 4, 2025. This fixed-price contract with economic price adjustment was issued by the Medical Supply Chain, a defense-focused federal agency, with no set-aside designation applied. APLIGRAF is an advanced wound care and tissue regeneration product that falls within Organogenesis's core portfolio...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a leading regenerative medicine company. The contract, valued at $4,645.00, is for the supply of PURAPLY MZ 500MG, a regenerative wound care product. Organogenesis is a for-profit organization and a manufacturer of goods. The contract does not utilize any set-aside designations. This delivery order is part of a larger $49.5 million multiple-award Indefinite Delivery...